Summary: Evaluated 17,802 low risk patients with normal low density lipoprotein (LDL) levels without known vascular disease or diabetes who had elevated CRP levels with either rosuvastatin 20 mg daily or placebo. The primary endpoint of a significant decrease in first major cardiovascular event (myocardial infarction, stroke, unstable angina, coronary revascularization or cardiac death) was reduced with rosuvastatin.
N Engl J Med. 2008 Nov 20;359(21):2195-207.
Eponym: Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin